Kidney cancer vaccine trial pulled before it began
NCT ID NCT06708936
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase study aimed to test a new vaccine called KSD-201 in people with advanced clear cell renal cell carcinoma whose cancer had stopped responding to standard treatments. The vaccine uses the patient's own immune cells to try to fight the cancer. However, the trial was withdrawn before any participants were enrolled, so no data on safety or effectiveness were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KSD-201 (dendritic cell vaccine)
What this could lead to
If it works, this could point toward a new vaccine-based treatment for advanced kidney cancer that has stopped responding to standard therapy.
What could go wrong
This trial was withdrawn before enrolling any participants, so no results are available. It was an early-phase study with a small planned sample, so even if conducted, success would be uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA (CCRCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 430000, China